Article

PDT laser receives expedited review status

The FDA has accepted for filing and granted expedited review status to the Miravant Medical Technologies' premarket application for the IRIS Medical OcuLight 664 ophthalmic photodynamic therapy (PDT) laser used to activate drug SnET2, a proposed drug and light treatment for patients with wet age-related macular degeneration (AMD).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
Related Content
Navigate successful cataract surgery with refractive technology
July 11th 2025

Navigate successful cataract surgery with refractive technology

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients
July 10th 2025

Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair
July 10th 2025

Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair

PulseSight doses first patient in PST-611-CT1
July 9th 2025

PulseSight doses first patient in PST-611-CT1

© 2025 MJH Life Sciences

All rights reserved.